Profile data is unavailable for this security.
About the company
SEIKAGAKU CORPORATION is principally engaged in the research, development, purchase, manufacture and sale of pharmaceutical products and limulus amebocyte lysate (LAL). The Company operates in two business segments. The Pharmaceutical business segment provides hyaluronan-based medicines for joint function improvement, ophthalmic operation boosters and submucosal injection materials for endoscopes, as well as drug substances for various pharmaceuticals. The LAL business segment provides reagents for measuring endotoxin.
- Revenue in JPY (TTM)35.86bn
- Net income in JPY-755.00m
- Incorporated1947
- Employees1.08k
- LocationSeikagaku Corp10F, Marunouchi Center Bldg1-6-1, MarunouchiCHIYODA-KU 100-0005JapanJPN
- Phone+81 352208950
- Fax+81 352208951
- Websitehttps://www.seikagaku.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astena Holdings Co Ltd | 62.74bn | 2.19bn | 20.71bn | 1.42k | 9.29 | 0.7507 | 4.50 | 0.3301 | 54.22 | 54.22 | 1,555.72 | 671.41 | 0.8961 | 3.62 | 2.88 | -- | 3.11 | 0.9587 | 6.26 | 1.76 | 34.85 | 30.40 | 3.47 | 1.05 | 0.9228 | -- | 0.4519 | 114.25 | 8.19 | -0.808 | 186.60 | 1.97 | 12.61 | 2.38 |
| Fuso Pharmaceutical Industries Ltd | 62.17bn | -4.01bn | 22.87bn | 1.34k | -- | 0.5962 | -- | 0.3679 | -469.00 | -469.00 | 7,280.21 | 4,059.08 | 0.7307 | 3.25 | 2.32 | 46,394,780.00 | -4.71 | 0.7682 | -9.76 | 1.29 | 26.39 | 26.94 | -6.44 | 1.05 | 0.8228 | 69.88 | 0.4617 | 106.29 | 9.31 | 5.25 | -338.78 | -- | 4.37 | 6.45 |
| Kubota Pharmaceutical Holdings Co Ltd | 21.34m | -676.25m | 23.66bn | 19.00 | -- | 13.04 | -- | 1,108.88 | -10.91 | -10.91 | 0.3341 | 15.72 | 0.0121 | 3.54 | 7.98 | -- | -38.41 | -44.81 | -42.10 | -49.35 | -14.68 | -- | -3,169.69 | -8,411.59 | 12.49 | -- | 0.0121 | -- | -21.53 | -10.80 | 49.26 | -- | -4.55 | -- |
| Renascience Inc | 106.94m | -258.99m | 24.51bn | 3.00 | -- | 9.94 | -- | 229.21 | -20.35 | -20.35 | 8.40 | 186.09 | 0.0479 | -- | 4.86 | 35,648,000.00 | -11.59 | -8.97 | -12.40 | -9.35 | 95.94 | 84.44 | -242.17 | -107.53 | -- | -- | 0.00 | -- | -31.66 | 13.00 | 143.91 | -- | -- | -- |
| RaQualia Pharma Inc | 3.98bn | 273.12m | 26.30bn | 85.00 | 112.75 | 3.59 | 34.55 | 6.61 | 8.97 | 8.97 | 165.54 | 281.96 | 0.3947 | 4.35 | 3.04 | -- | 2.71 | 2.64 | 3.08 | 2.90 | 82.11 | 85.46 | 6.86 | 6.36 | 4.33 | 6.63 | 0.2962 | 0.00 | 28.07 | 29.16 | 155.17 | -- | -13.74 | -- |
| Seikagaku Corp | 35.86bn | -755.00m | 40.91bn | 1.08k | -- | 0.5385 | 30.69 | 1.14 | -13.84 | -13.84 | 656.96 | 1,337.18 | 0.4328 | 2.03 | 3.92 | 33,360,930.00 | -0.9099 | 3.60 | -0.9881 | 3.96 | 40.92 | 52.56 | -2.10 | 7.94 | 4.26 | -- | 0.0049 | 55.17 | 8.73 | 6.57 | -44.46 | -- | 18.48 | 2.90 |
| Daito Pharmaceutical Co Ltd | 51.20bn | 2.23bn | 42.38bn | 1.07k | 18.92 | 0.7984 | 6.39 | 0.8277 | 74.42 | 74.42 | 1,703.91 | 1,763.62 | 0.6544 | 2.16 | 2.76 | 47,716,680.00 | 2.90 | 5.12 | 3.71 | 6.67 | 17.63 | 21.75 | 4.43 | 7.35 | 1.31 | -- | 0.1739 | 24.48 | 7.99 | 2.39 | -42.09 | -13.52 | 20.45 | 14.00 |
| Fuji Pharma Co Ltd | 54.57bn | 2.33bn | 58.82bn | 1.76k | 24.75 | 1.21 | 9.35 | 1.08 | 95.46 | 95.46 | 2,233.29 | 1,959.48 | 0.5765 | 1.49 | 2.83 | 31,007,950.00 | 2.46 | 4.51 | 3.93 | 6.76 | 40.82 | 40.57 | 4.27 | 8.51 | 0.876 | 17.58 | 0.3885 | 25.98 | 12.01 | 8.87 | -51.19 | 7.55 | 8.07 | 7.94 |
Data as of Feb 20 2026. Currency figures normalised to Seikagaku Corp's reporting currency: Japanese Yen JPY
12.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invesco Asset Management (Japan) Ltd.as of 31 Jul 2025 | 2.72m | 4.78% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 1.30m | 2.29% |
| Nomura Asset Management Co., Ltd.as of 05 Feb 2026 | 1.15m | 2.03% |
| Amova Asset Management Co., Ltd.as of 06 Feb 2026 | 492.80k | 0.87% |
| Daiwa Asset Management Co. Ltd.as of 30 Jan 2026 | 473.20k | 0.83% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 11 Aug 2025 | 354.70k | 0.62% |
| Dimensional Fund Advisors LPas of 31 Jan 2026 | 282.80k | 0.50% |
| Bessemer Investment Management LLCas of 31 Oct 2025 | 125.20k | 0.22% |
| Invesco Hong Kong Ltd.as of 13 Sep 2024 | 99.90k | 0.18% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 95.20k | 0.17% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
